NRC Proposes Modernized Rules for Medical and Industrial Radioactive Materials

Hospitals, industrial radiography firms and research labs could get a faster, less duplicative path through the Nuclear Regulatory Commission’s radioactive-materials rules if the agency’s May 7 proposal survives comment and final approval. The package would create a new class of general licenses for routine uses, update financial assurance thresholds, cut paperwork for low-risk consumer and commercial products, and give more flexibility to PET isotope distribution.

The practical change is simple: less time spent working through overlapping paperwork, more time moving material into patient care, field work and lab use. The NRC said the overhaul would streamline licensing for medical imaging, cancer diagnostics, industrial radiography and well logging, while also easing navigation across different regulatory jurisdictions. That matters for suppliers that operate nationwide and currently face separate layers of oversight in Agreement States and NRC-regulated areas.

The commission said the rewrite was meant to preserve safety while stripping out requirements that no longer match current technology or risk. Chairman Ho Nieh framed it as a smarter, more modern approach to regulation, and the agency said it had already prepared plain-language guidance, reciprocity material and draft implementation tools so applicants and licensees can adjust if the rule is finalized. The Federal Register notice was slated for May 20, though the date could change.

The proposal sits on top of a sprawling materials framework that now stretches across Parts 19, 20, 21, 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70, 71, 110, 150.20, 170 and 171. NRC guidance for medical, academic and industrial users is compiled in NUREG-1556 Volumes 1 through 21, and the agency says it licenses possession and use of byproduct, source and special nuclear material for those sectors. In other words, this is not a narrow tweak. It is a rule rewrite that could ripple through hospital medicine, isotope supply chains and industrial field work at the same time.

The timing also fits a broader regulatory push. The Advisory Committee on the Medical Uses of Isotopes met April 20 and 21, 2026, with agenda items that included ADVANCE Act implementation, alpha nuclides in radiopharmaceutical therapy, AI and deep learning in NRC medical review work, and a tentative look at the modernizing physical-protection rulemaking. The NRC had already been revisiting patient-release policy in 2023 with draft guide DG-8061, which addressed release after radiopharmaceuticals or implants. For now, the agency is betting that clearer rules and lighter friction will lower costs without punching holes in the guardrails that still matter most.